Journals / Psychiatry and behavioral sciences (Online) / 2020 / Cilt: 10 - Sayı: 4

Psychotic Episodes After Vigabatrine Treatment: A Case Report

Pages
216–218
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We discussed the possible mechanisms of psychosis that can be seen in the use of vigabatrin in the light of the assumptions that GABA, glutamate and dopamine are involved in the formation of positive symptoms in psychosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Vigabatrin is an antiepileptic that functions by increasing ɣ-aminobutyric acid (GABA) levels in the brain.
📊
Key Findings & Data:Like other antiepileptics, it also causes neuropsychiatric side effects.
💡
Conclusion & Impact:We discussed the possible mechanisms of psychosis that can be seen in the use of vigabatrin in the light of the assumptions that GABA, glutamate and dopamine are involved in the formation of positive symptoms in psychosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Vigabatrin is an antiepileptic that functions by increasing ɣ-aminobutyric acid (GABA) levels in the brain. Like other antiepileptics, it also causes neuropsychiatric side effects. Among these side effects, psychosis draws particular attention. Drug-induced psychosis has been reported in previous publications at the beginning of the drug, while psychosis reports during the cessation period are limited. We discussed the possible mechanisms of psychosis that can be seen in the use of vigabatrin in the light of the assumptions that GABA, glutamate and dopamine are involved in the formation of positive symptoms in psychosis.

🔖

Cite This Article

UYSAL, E., KONKAN, R. (2020). Psychotic Episodes After Vigabatrine Treatment: A Case Report. Psychiatry and behavioral sciences (Online), Cilt: 10 - Sayı: 4, 216–218. https://ajindex.com/articles/302800

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Trimble MR, Rüsch N, Betts T, Crawford M P. Psychiatric symptoms after therapy with new antiepileptic drugs: Psychopathological and seizure related variables. Seizure. 2000; 9: 249–254
  2. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia.2009; 50(2):163–173
  3. Walker SD, Kälviäinen R. Non-vision adverse events with vigabatrin therapy. Acta Neurol Scand. 2011;124 (Suppl 192): 72-82
  4. Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: An analysis of food and drug administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007;15;62(4):345-354
  5. Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology 1999; 53:1503–1511
  6. Krishnamoorthy ES, Trimble MR, Sander JWAS, Kanner AM. Forced normalization at the interface between epilepsy and psychiatry. Epilepsy Behav. 2002; 3(4):303–308
  7. Weber P, Dill P, Datta AN. Vigabatrin-induced forced normalization and psychosis — Prolongated termination of behavioral symptoms but persistent antiepileptic effect after withdrawal. Epilepsy Behav. 2012; 24(1): 138–140
  8. Piedad P, Rickards H, Besag FMC, Cavanna AE. Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy A summary of prevalence, underlying mechanisms and data limitations. CNS Drugs 2012; 26 (4): 319-335
  9. De Toffol B, Trimble M, Hesdorffer DC, Taylor L, Sachdev P, Clancy M, Adachi N, Bragatti JA, Mula M, Kanemoto K. Pharmacotherapy in patients with epilepsy and psychosis. Epilepsy Behav.2018;88: 54–60
  10. Besag FMC. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf. 2004;3(1):1-8.